"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
Do not exceed indicated recommended dosage as overdosage levels have not been identified for Lymphazurin (isosulfan blue) 1%.
Lymphazurin™ 1% (isosulfan blue) is contraindicated in those individuals with known hypersensitivity to triphenylmethane or related compounds.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/13/2008
Additional Lymphazurin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.